We have previously reported a 100% match of the MYD88 mutation status in circulating tumor DNA (ctDNA) extracted from cerebrospinal fluid (CSF) and biopsied tissue in 21 primary and secondary central nervous system lymphoma patients using droplet digital PCR (ddPCR) [8]. This evidence concerns the gene MYD88 and neoplasm.